Compare SCD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | NBTX |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | SCD | NBTX |
|---|---|---|
| Price | $14.78 | $23.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 62.6K | 30.6K |
| Earning Date | 01-01-0001 | 09-30-2025 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,930,711.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $145.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.33 | $2.82 |
| 52 Week High | $15.87 | $30.35 |
| Indicator | SCD | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 58.15 |
| Support Level | $14.53 | $21.44 |
| Resistance Level | $14.74 | $24.01 |
| Average True Range (ATR) | 0.15 | 0.87 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 45.18 | 73.94 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.